MDA 2024: Benefits of Zilbrysq sustained over 1 year in gMG study
Study data show long-term treatment with Zilbrysq led to sustained reductions in disease severity in generalized myasthenia gravis patients.| Myasthenia Gravis News
Study data show long-term treatment with Zilbrysq led to sustained reductions in disease severity in generalized myasthenia gravis patients.| Myasthenia Gravis News
Lindsey Shapiro is a science writer for Myasthenia Gravis News with a PhD in neuroscience. She covers the latest news and information on a variety of myasthenia gravis topics.| Myasthenia Gravis News
IImmunovant is prioritizing IMVT-1402 as its lead MG treatment candidate, with registrational clinical trials possible in the next year.| Myasthenia Gravis News
Category archive page for News.| Myasthenia Gravis News
